Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.66 USD | -0.35% | +8.64% | -1.74% |
Jul. 11 | Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors | CI |
May. 13 | Transcript : Journey Medical Corporation, Q1 2024 Earnings Call, May 13, 2024 |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 89.63 | 34.11 | 106.6 | 113.3 | - | - |
Enterprise Value (EV) 1 | 89.63 | 34.11 | 106.6 | 113.3 | 113.3 | 113.3 |
P/E ratio | -1.25 x | -1.14 x | -27.4 x | -6.15 x | 340 x | -23.6 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 1.42 x | 0.46 x | 1.35 x | 1.99 x | 1.32 x | 1.48 x |
EV / Revenue | 1.42 x | 0.46 x | 1.35 x | 1.99 x | 1.32 x | 1.48 x |
EV / EBITDA | -3 x | -4.68 x | 6.84 x | 47.3 x | 5.64 x | - |
EV / FCF | -41,095,321 x | - | - | - | - | - |
FCF Yield | -0% | - | - | - | - | - |
Price to Book | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 16,660 | 17,766 | 18,508 | 20,013 | - | - |
Reference price 2 | 5.380 | 1.920 | 5.760 | 5.660 | 5.660 | 5.660 |
Announcement Date | 3/28/22 | 3/29/23 | 3/21/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | 63.13 | 73.67 | 79.18 | 56.82 | 85.98 | 76.46 |
EBITDA 1 | - | -29.84 | -7.283 | 15.59 | 2.394 | 20.1 | - |
EBIT 1 | - | -34.88 | -27.52 | -2.073 | -17.51 | -13.25 | -4.337 |
Operating Margin | - | -55.25% | -37.35% | -2.62% | -30.81% | -15.41% | -5.67% |
Earnings before Tax (EBT) 1 | - | -42.36 | -29.56 | -3.632 | -17.92 | 1.677 | -5.152 |
Net income 1 | 5.283 | -43.99 | -29.63 | -3.853 | -17.92 | 0.4457 | -5.152 |
Net margin | - | -69.68% | -40.22% | -4.87% | -31.53% | 0.52% | -6.74% |
EPS 2 | 0.4900 | -4.320 | -1.690 | -0.2100 | -0.9200 | 0.0167 | -0.2400 |
Free Cash Flow | - | -2.181 | - | - | - | - | - |
FCF margin | - | -3.45% | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 7/22/21 | 3/28/22 | 3/29/23 | 3/21/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 17.52 | 23.3 | 18.29 | 16.12 | 15.97 | 12.21 | 17.17 | 34.54 | 15.26 | 13.03 | 13.88 | 14.54 | 14.74 | 14.08 | 19.42 |
EBITDA 1 | -4.708 | 2.308 | -2.571 | -4.019 | -3.001 | -5.86 | -0.639 | 20.82 | 0.724 | 0.011 | 0.7025 | 0.8875 | 0.794 | 1.404 | 1.562 |
EBIT 1 | -9.057 | -0.888 | -7.142 | -9.492 | -9.995 | -9.561 | -7.653 | 17.24 | -2.104 | -10.09 | -2.724 | -3.207 | -3.368 | - | - |
Operating Margin | -51.7% | -3.81% | -39.05% | -58.9% | -62.6% | -78.29% | -44.57% | 49.93% | -13.79% | -77.44% | -19.62% | -22.05% | -22.84% | - | - |
Earnings before Tax (EBT) 1 | -13.42 | -1.274 | -7.592 | -10.07 | -10.63 | -10.14 | -8.363 | 16.88 | -2.017 | -10.44 | -2.744 | -2.661 | -2.705 | -1.3 | -1.1 |
Net income 1 | -21.75 | -1.378 | -7.528 | -10.08 | -10.64 | -10.14 | -8.363 | 16.79 | -2.143 | -10.44 | -2.744 | -2.661 | -2.705 | -1.027 | -0.869 |
Net margin | -124.17% | -5.92% | -41.16% | -62.55% | -66.65% | -82.99% | -48.7% | 48.61% | -14.05% | -80.14% | -19.77% | -18.3% | -18.35% | -7.29% | -4.48% |
EPS 2 | -1.890 | -0.0800 | -0.4300 | -0.5700 | -0.6000 | -0.5700 | -0.4600 | 0.8000 | -0.1200 | -0.5300 | -0.1433 | -0.1400 | -0.1400 | -0.0500 | -0.0400 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 3/28/22 | 5/10/22 | 8/9/22 | 11/10/22 | 3/29/23 | 5/22/23 | 8/8/23 | 11/7/23 | 3/21/24 | 5/13/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow | - | -2.18 | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex | - | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - | - |
Announcement Date | 7/22/21 | 3/28/22 | 3/29/23 | 3/21/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.74% | 113M | |
+62.66% | 854B | |
+40.42% | 636B | |
-4.37% | 361B | |
+17.16% | 324B | |
+9.87% | 301B | |
+15.66% | 247B | |
+17.90% | 228B | |
+14.86% | 177B | |
+0.45% | 164B |
- Stock Market
- Equities
- DERM Stock
- Financials Journey Medical Corporation